|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shiels MS, Pfeiffer RM, Hildesheim A,
Engels EA, Kemp TJ, Park JH, Katki HA, Koshiol J, Shelton G,
Caporaso NE, et al: Circulating inflammation markers and
prospective risk for lung cancer. J Natl Cancer Inst.
105:1871–1880. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Straif K, Benbrahim-Tallaa L, Baan R,
Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Guha N, Freeman C,
Galichet L, et al: WHO International Agency for Research on Cancer
Monograph Working Group: A review of human carcinogens--Part C:
Metals, arsenic, dusts, and fibres. Lancet Oncol. 10:453–454. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edge SB, Byrd DR, Compton CC, et al: AJCC
Cancer Staging Manual. 7th. Springer; New York: 2010
|
|
5
|
Yotsukura M, Ohtsuka T, Kaseda K, Kamiyama
I, Hayashi Y and Asamura H: Value of the Glasgow Prognostic Score
as a Prognostic Factor in Resectable Non-Small Cell Lung Cancer. J
Thorac Oncol. 11:1311–1318. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sholl LM, Aisner DL, Varella-Garcia M,
Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler
K, Franklin WA, et al: LCMC Investigators: Multi-institutional
Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung
Cancer Mutation Consortium Experience. J Thorac Oncol. 10:768–777.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dinarello CA: Biologic basis for
interleukin-1 in disease. Blood. 87:2095–2147. 1996.PubMed/NCBI
|
|
8
|
Konishi N, Miki C, Yoshida T, Tanaka K,
Toiyama Y and Kusunoki M: Interleukin-1 receptor antagonist
inhibits the expression of vascular endothelial growth factor in
colorectal carcinoma. Oncology. 68:138–145. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barillé S, Akhoundi C, Collette M,
Mellerin MP, Rapp MJ, Harousseau JL, Bataille R and Amiot M:
Metalloproteinases in multiple myeloma: Production of matrix
metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction
of MMP-1 by myeloma cells. Blood. 90:1649–1655. 1997.PubMed/NCBI
|
|
10
|
Apte RN and Voronov E: Interleukin-1--a
major pleiotropic cytokine in tumor-host interactions. Semin Cancer
Biol. 12:277–290. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dinarello CA: Interleukin-1 and
interleukin-1 antagonism. Blood. 77:1627–1652. 1991.PubMed/NCBI
|
|
12
|
Lewis AM, Varghese S, Xu H and Alexander
HR: Interleukin-1 and cancer progression: The emerging role of
interleukin-1 receptor antagonist as a novel therapeutic agent in
cancer treatment. J Transl Med. 4:482006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Voronov E, Carmi Y and Apte RN: Role of
IL-1-mediated inflammation in tumor angiogenesis. Adv Exp Med Biol.
601:265–270. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smith DR, Kunkel SL, Standiford TJ,
Chensue SW, Rolfe MW, Orringer MB, Whyte RI, Burdick MD, Danforth
JM, Gilbert AR, et al: The production of interleukin-1 receptor
antagonist by human bronchogenic carcinoma. Am J Pathol.
143:794–803. 1993.PubMed/NCBI
|
|
15
|
Fuksiewicz M, Kaminska J, Kotowicz B,
Kowalska M, Rubach M and Pienkowski T: Serum cytokine levels and
the expression of estrogen and progesterone receptors in breast
cancer patients. Clin Chem Lab Med. 44:1092–1097. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Barber MD, Ross JA and Fearon KC: Changes
in nutritional, functional, and inflammatory markers in advanced
pancreatic cancer. Nutr Cancer. 35:106–110. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bruserud O, Aasen I, Akselsen PE, Bergheim
J, Rasmussen G and Nesthus I: Interleukin 1 receptor antagonist
(IL1RA) in acute leukaemia: IL1RA is both secreted spontaneously by
myelogenous leukaemia blasts and is a part of the acute phase
reaction in patients with chemotherapy-induced leucopenia. Eur J
Haematol. 57:87–95. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Danis VA, Millington M, Hyland VJ and
Grennan D: Cytokine production by normal human monocytes:
Inter-subject variation and relationship to an IL-1 receptor
antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol.
99:303–310. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu Z, Shao M, Chen Y, Zhou J, Qian J, Xu
L, Ma H, Wang X, Xu Y, Lu D, et al: Allele 2 of the interleukin-1
receptor antagonist gene (IL1RN*2) is associated with a decreased
risk of primary lung cancer. Cancer Lett. 236:269–275. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hurme M and Santtila S: IL-1 receptor
antagonist (IL-1Ra) plasma levels are co-ordinately regulated by
both IL-1Ra and IL-1β genes. Eur J Immunol. 28:2598–2602. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lind H, Zienolddiny S, Ryberg D, Skaug V,
Phillips DH and Haugen A: Interleukin 1 receptor antagonist gene
polymorphism and risk of lung cancer: A possible interaction with
polymorphisms in the interleukin 1 beta gene. Lung Cancer.
50:285–290. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McKeown DJ, Brown DJ, Kelly A, Wallace AM
and McMillan DC: The relationship between circulating
concentrations of C-reactive protein, inflammatory cytokines and
cytokine receptors in patients with non-small-cell lung cancer. Br
J Cancer. 91:1993–1995. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Herfs M, Hubert P, Poirrier AL, Vandevenne
P, Renoux V, Habraken Y, Cataldo D, Boniver J and Delvenne P:
Proinflammatory cytokines induce bronchial hyperplasia and squamous
metaplasia in smokers: Implications for chronic obstructive
pulmonary disease therapy. Am J Respir Cell Mol Biol. 47:67–79.
2012. View Article : Google Scholar : PubMed/NCBI
|
